Innealta Capital’s Travere Therapeutics TVTX Stock Holding History

Innealta Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28	Closed	-$230	–	1570
2024 Q2	$230	Buy	+28	New	+$189	﹤0.01%	1587

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Innealta Capital's TVTX Position: Q3 2024 in Review

Innealta Capital sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 28 shares — an estimated $230 sold.

Innealta Capital first reported a position in TVTX in Q2 2024 and held it in 1 quarter. The position peaked at $230 in Q2 2024. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

Innealta Capital reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 28 Travere Therapeutics shares in Q3 2024, an estimated $230.
Innealta Capital first reported a position in Travere Therapeutics in Q2 2024 and held it in 1 quarter.
Innealta Capital's Travere Therapeutics position peaked at $230 in Q2 2024.
178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.